表紙
市場調查報告書

大腸癌症診斷藥·治療藥的全球市場 - 成長·趨勢·預測

Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353905
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
Back to Top
大腸癌症診斷藥·治療藥的全球市場 - 成長·趨勢·預測 Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年04月01日內容資訊: 英文 113 Pages
簡介

面向本報告彙整全球大腸癌症診斷藥及治療藥的市場相關分析,彙整市場基本結構和最新形勢,主要的推動及阻礙市場要素,市場規模趨勢預測 (今後6年份),模式 (各診斷/治療法) 及地區別詳細趨勢,市場競爭的動向 (各種資本交易等),主要企業的簡介等資訊,為您概述為以下內容。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析

第5章 市場區隔

  • 模式 (手法) 別
    • 診斷法
      • 驗便
      • 免疫組織化學 (IHC)
      • 大腸內視鏡檢驗
      • 軟性S字結腸鏡檢驗
      • 其他診斷法
    • 治療方法
      • 化療
        • 代謝拮抗劑
          • Fluorouracil
          • Capecitabine
        • 烷化劑
          • 奧沙利鉑(Oxaliplatin)
        • 其他
      • 免疫療法
        • Bevacizumab
        • Cetuximab
        • panitumumab
      • 癌症防禦物質
      • 其他
  • 各地區
    • 北美 (美國,加拿大,墨西哥等)
    • 歐洲 (德國,英國,法國,義大利,西班牙等)
    • 亞太地區 (中國,日本,印度,澳洲,韓國等)
    • 中東·非洲 (波灣合作理事會 (GCC) 各國,南非等)
    • 南美 (巴西,阿根廷等)

第6章 競爭環境

  • 企業簡介
    • Abbott Laboratories
    • Amgen Inc.
    • Clinical Genomics
    • EDP Biotech
    • Epigenomics AG
    • F. Hoffmann-La Roche AG
    • Novigenix SA
    • Quest Diagnostics
    • Sanofi SA
    • Siemens Healthineers
    • VolitionRX

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 50590

Market Overview

The colorectal cancer diagnostics and therapeutics market are expected to register a CAGR of nearly 4.6% during the forecast period, 2019-2024.

  • Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.
  • According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030.
  • Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.
  • According to a research article published in 2016, "Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States".
  • Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.

Scope of the Report

Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, and is any form of cancer that affects the colon and the rectum. The report tracks revenue generated by therapeutics used for the management of colorectal cancer, along with various screening tests, kits, and medical devices used for the diagnosis of colorectal cancer.

Key Market Trends

Immunotherapy Blockbusters to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

Bevacizumab (Avastin) is a monoclonal antibody that prevents tumors from growing in blood vessels, by antagonizing vascular endothelial growth factor (VEGF), which is a substance released by tumors to stimulate new blood vessel formation. The FDA approved a labeling extension for bevacizumab, administered in combination with intravenous 5-fluorouracil-based chemotherapy, for the second-line treatment of metastatic carcinoma of the colon or rectum. The approval of cyramza (ramucirumab) for second-line Avastin pre-treated metastatic setting, in 2016, is expected to propel the growth of the colorectal cancer drugs market, in the future.

The United States is Expected to Retain Largest Market Share During the Forecast Period

Geographically, the United States holds the largest market share with respect to demand and revenue. In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market. The Asia-Pacific is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress. In 2015, Roche signed an agreement with an insurance company in Shenzhen City. The Chinese people were among the first few to approve Avastin for reimbursement. This is expected to increase access to colorectal cancer therapeutics in China.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics segment. Key players in the market include Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Radiology and Chemotherapy
    • 4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Drugs
    • 4.3.2 Side Effects Associated With Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Modality
    • 5.1.1 Diagnostics Techniques
      • 5.1.1.1 Stool Tests
      • 5.1.1.2 Immunohistochemistry
      • 5.1.1.3 Colonoscopy
      • 5.1.1.4 Flexible Sigmoidoscopy
      • 5.1.1.5 Other Diagnostics Techniques
    • 5.1.2 Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.1.1 Antimetabolites
      • 5.1.2.1.1.1 Fluorouracil
      • 5.1.2.1.1.2 Capecitabine
      • 5.1.2.1.2 Alkylating Agent
      • 5.1.2.1.2.1 Oxaliplatin
      • 5.1.2.1.3 Other Chemotherapeutic Agents
      • 5.1.2.2 Immunotherapy
      • 5.1.2.2.1 Bevacizumab
      • 5.1.2.2.2 Cetuximab
      • 5.1.2.2.3 Panitumumab
      • 5.1.2.3 Chemoprotectant
      • 5.1.2.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Clinical Genomics
    • 6.1.4 EDP Biotech
    • 6.1.5 Epigenomics AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Novigenix SA
    • 6.1.8 Quest Diagnostics
    • 6.1.9 Sanofi SA
    • 6.1.10 Siemens Healthineers
    • 6.1.11 VolitionRX

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top